| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci |
NCT06114940: Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC |
|
|
| Recruiting | 2 | 32 | RoW | Toripalimab, anti-PD-1 monoclonal antibody, Lenvatinib, Lenvatinib mesylate (USAN) | Jinling Hospital, China | Neoplasms, Kidney Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Female Urogenital Diseases, Urogenital Diseases, Kidney Diseases, Urologic Diseases, Male Urogenital Diseases, Carcinoma, Carcinoma, Renal Cell, Antineoplastic Agents, Immune Checkpoint Inhibitors | 12/25 | 12/25 | | |
ChiCTR2300067960: A single-arm, phase II trial about adjuvant Toripalimab treating locally advanced patients with head and neck squamous carcinoma who achieved complete pathological response after neoadjuvant chemoimmunotherapy and surgery |
|
|
| Not yet recruiting | 2 | 25 | China | Toripalimab, 240mg Q3W, 8 cycles | Sun Yat-sen University Cancer Center ; Sun Yat-sen University Cancer Center, Junshi Biosciences (Shanghai) Co.,Ltd | Head and neck squamous carcinoma | | | | |
NCT05773079: Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 28 | NA | Toripalimab | Nanfang Hospital, Southern Medical University | Locally Advanced Head and Neck Squamous Cell Carcinoma | 02/26 | 06/28 | | |
| Not yet recruiting | 2 | 50 | China | toripalimab + cetuximab | Fudan University Cancer Hospital ; Fudan University Cancer Hospital, Fudan University Cancer Hospital | colorectal cancer | | | | |
NCT05729646: Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Toripalimab, Oxaliplatin, S1 | Yu jiren | Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency | 02/26 | 02/29 | | |
| Recruiting | 2 | 45 | RoW | endoscopic surgery, radiotherapy, chemotherapy, Toripalimab | Eye & ENT Hospital of Fudan University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Malignant Melanoma, Sinonasal Melanoma | 05/26 | 05/26 | | |
NCT06065813: Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 20 | RoW | Toripalimab, JS001, Conventional segmental radiotherapy, opreation | Northern Jiangsu Province People's Hospital, Shanghai Junshi Bioscience Co., Ltd. | Non-small Cell Lung Cancer, Neoadjuvant Therapy, Radiotherapy, Immunotherapy | 05/26 | 05/26 | | |
ChiCTR2100045797: Phase II, single-arm, prospective clinical study of Toripalimab combined with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma after endoscopic surgery |
|
|
| Recruiting | 2 | 45 | | endoscopic therapy, immunity treatment,radiation,chemotherapy | Eye, Ear, Nose and Throat Hospital, Fudan University; Eye, Ear, Nose, and Throat Hospital, Fudan University, Research Units of New Technologies of Endoscopic Surgery in Skull Base Tumor(2018RU003),Chinese Academy of Medical Sciences，Shanghai Science and Technology Committee et.al | sinonasal malignant mucosal melanoma | | | | |
ChiCTR2300073467: PD-1 inhibitor combined with nimotuzumab and gemcitabine plus cisplatin for the first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma: a single arm, phase II clinical study |
|
|
| Recruiting | 2 | 26 | China | The first stage is the PD-1 inhibitor plus nimotuzumab and chemotherapy combination treatment, 21 days is a cycle, a total of 4-6 cycles, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion, day 0 (one day before chemotherapy); Nimotuzumab, intravenous infusion, on day 0 (one day before chemotherapy); Chemotherapy: Gemcitabine, intravenous infusion, day 1 and 8, (1000mg/m2), Cisplatin, intravenous infusion, day 1 (80mg/ m2). The second stage is the maintenance treatment, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion (day 1, every 3 weeks); Capecitabine (650mg/m2, take orally, two times every day); PD-1 inhibitor and Capecitabine should be administered until the end of the study. | Dongguan People's Hospital ; Dongguan People's Hospital, Biotech Pharmaceutical Co., Ltd | nasopharyngeal carcinoma | | | | |
ChiCTR2200060097: Phase II clinical study of Toripalimab combined with induction chemotherapy and concurrent chemoradiotherapy in patients with stage IVa nasopharyngeal carcinoma |
|
|
| Recruiting | 2 | 72 | China | Toripalimab monoclonal antibody and modified TPF regimen | Yulin First People's Hospital ; Yulin First People's Hospital, self-raised | Nasopharyngeal carcinoma | | | | |
NCT05962021: Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation |
|
|
| Not yet recruiting | 2 | 126 | NA | Toripalimab plus Chemotherapy | Peking University People's Hospital, Shanghai Junshi Bioscience Co., Ltd. | Non Squamous Non Small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer | 06/26 | 06/26 | | |
NCT05628922: Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT |
|
|
| Recruiting | 2 | 198 | RoW | Toripalimab, JS001, Induction chemotherapy and concurrent chemoradiation | Fudan University | Nasopharyngeal Cancer | 07/26 | 07/27 | | |
NCT05970627: Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | Toripalimab, Oxaliplatin, S1 | Yu jiren | Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma | 07/26 | 07/29 | | |
NeoTPD01, NCT04304248: Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 30 | RoW | Albumin-bound paclitaxel, Carboplatin, Toripalimab | Hao Long | Non Small Cell Lung Cancer | 07/26 | 07/26 | | |
ChiCTR2200062880: A single-arm, open-label, prospective, single-center phase II clinical trial of antiangiogenic chemoradiotherapy combined with toripalimab in first-line treatment of advanced malignant melanoma |
|
|
| Not yet recruiting | 2 | 40 | China | nab-paclitaxel, bevacizumab, toripalimab, radiotherapy | Nanjing Drum Tower Hospital ; Nanjing Drum Tower Hospital, Self-funded | advanced malignant melanoma | | | | |
IUNU-RC, NCT05768464: Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors |
|
|
| Recruiting | 2 | 30 | RoW | Toripalimab, anti-PD-1 monoclonal antibody, Axitinib, TKI | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Non-clear Renal Cell Carcinoma | 12/26 | 12/27 | | |
| Recruiting | 2 | 35 | China | High and low dose radiotherapy combined with Toripalimab | The Second Affiliated Hospital of Nanchang University ; The Second Affiliated Hospital of Nanchang University, The Second Affiliated Hospital of Nanchang University | Nasopharyngeal carcinoma | | | | |
ChiCTR2200056870: An open, multicenter, single-arm, phase II study evaluating triplimumab injection (JS001) combined with chemotherapy for neoadjuvant treatment of gastric/gastroesophageal junction cancer |
|
|
| Not yet recruiting | 2 | 40 | China | Toripalimab injection (JS001) combined with capecitabine and oxaliplatin | Guangdong Provincial People's Hospital ; Guangdong Provincial People's Hospital, Tririplizumab injection (JS001) was provided free of charge by Shanghai Junshi Biomedical Technology Co., LTD. | gastric/gastroesophageal junction carcinoma | | | | |
ChiCTR2100042602: Toripalimab combined with IMRT for nasopharyngeal carcinoma with unsatisfactory response or detectable EBV DNA after induction chemotherapy: a prospective, single-arm, phase II clinical trial |
|
|
| Recruiting | 2 | 34 | China | Toripalimab combined with IMRT (toripalimab 240mg every 3 weeks for 1 year or until confirming disease progression or unacceptable toxicity occurring) | Sun Yat-Sen University Cancer Center ; Sun Yat-Sen University Cancer Center, Junshi Bioscieces biopharmaceutical company presents 17 courses of toripalimab | nasopharyngeal carcinoma | | | | |
NCT05484375: Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment |
|
|
| Not yet recruiting | 2 | 40 | NA | Capecitabine plus toripalimab | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Hunan Cancer Hospital | Metastatic Nasopharyngeal Carcinoma | 09/27 | 09/29 | | |
NCT06039631: Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer |
|
|
| Recruiting | 2 | 82 | RoW | Surgery, Radiation, Toripalimab | Fudan University, Fudan University Eye Ear Nose and Throat Hospital, Shanghai Zhongshan Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Larynx Cancer, Hypopharyngeal Cancer | 09/27 | 09/29 | | |
ChiCTR2300075075: A Phase IIA Clinical Study of Toripalimab Combined with DCF Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 54 | | Toripalimab: intravenous infusion, once every 3 weeks, at a dose of 240 mg; 3 cycles in total; Chemotherapy: on the day of treatment, docetaxel + cisplatin + 5-FU (DCF) Q3W regimen chemotherapy, cisplatin 70 mg/m2 ivgtt d1, docetaxel 70 mg/m2 ivgtt d1, 5-FU 750 mg/m2 ivgtt d1-5, q21d were administered，3 cycles total. | Fujian Provincial Hospital; Fujian Provincial Hospital, Shanghai Junshi Bio-pharmaceutical Technology Co., Ltd. | Esophageal Squamous Cell Carcinoma | | | | |
NCT05917158: A Study of RC48-ADC Combined With JS00 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | RC48-ADC and JS001 | Jinling Hospital, China | Carcinoma, Upper Tract Urothelial Carcinoma, UTUC | 12/27 | 12/28 | | |
ChiCTR2300068574: A randomized clinical trial of postoperative adjuvant therapy with Toripalimab versus cervical lymphadenectomy alone for Residual recurrent nasopharyngeal carcinoma in cervical lymph nodes |
|
|
| Recruiting | 2 | 154 | China | Cervical lymphadenectomy + Toripalimab ;Cervical lymphadenectomy | Sun Yat-sen University Cancer Center ; Sun Yat-sen University Cancer Center, Shanghai Junshi Biosciences Co. Ltd. | Nasopharyngeal carcinoma | | | | |
ChiCTR2200060136: Nituzumab plus terriprizumab combined with GP versus nituzumab combined with GP in patients with high-risk locally advanced nasopharyngeal carcinoma: a multicenter, randomized controlled, open clinical study |
|
|
| Recruiting | 2 | 292 | China | Induction chemotherapy with teriprizumab plus nituzumab and GP followed by radical radiotherapy ;Induction chemotherapy with nituzumab and GP followed by chemoradiotherapy | Sun Yat-sen University Cancer Center ; Sun Yat-sen University Cancer Center, NA | nasopharyngeal carcinoma | | | | |
NCT04721223: JAB-3068 Activity in Adult Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1b/2a | 118 | RoW | JAB-3068, PD1 inhibitor | Jacobio Pharmaceuticals Co., Ltd., AbbVie | Advanced Solid Tumor, Esophageal Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 02/22 | 10/22 | | |
RC108-C004, CTR20232828: An open-label, single-arm, multicenter Phase Ib/II clinical study to evaluate the safety, tolerability, efficacy, and pharmacokinetic profile of RC108 in combination with toripalimab in patients with c-Met-expressing advanced solid tumors |
|
|
| Ongoing | 1b/2 | 178 | China | RC108 - Rongchang Pharma | Remegen Biopharmaceutical (Yantai) Co., Ltd | C-MET-expressing advanced solid tumors | | | | |
SCORPIO, NCT05986227: The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): |
|
|
| Not yet recruiting | 1b/2 | 126 | NA | toripalimab FOLFOX | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Gastroesophageal Adenocarcinoma | 07/25 | 07/26 | | |
NCT02915432: The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC |
|
|
| Active, not recruiting | 1/2 | 401 | RoW | 3 mg/kg anti-PD-1 mAb JS001 Q2W, toripalimab, TAB001, 360 mg anti-PD-1 mAb JS001 Q3W, 240mg anti-PD-1 mAb JS001 Q3W | Shanghai Junshi Bioscience Co., Ltd. | Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma | 02/20 | 04/22 | | |
| Recruiting | 1/2 | 30 | RoW | Toripalimab, Sorafenib | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 10/21 | 12/21 | | |
| Not yet recruiting | 1/2 | 30 | RoW | PD-1 antibody, Toripalimab | Peking University Third Hospital | Cervical Cancer | 12/21 | 12/22 | | |
ChiCTR2100042530: Combination of Toripalimab and preoperative Neoadjuvant chemoradiation for esophageal squamous cell carcinoma |
|
|
| Recruiting | 1/2 | 60 | China | Toripalimab ;Radiotherapy ;Paclitaxel + Carboplatin | The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) ; The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) | Esophageal Squamous Cell Carcinoma | | | | |
| Recruiting | 1/2 | 60 | RoW | ATG-008, Toripalimab | Sichuan University | Advanced Solid Tumor | 05/22 | 12/22 | | |
NCT03867370: Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma |
|
|
| Terminated | 1/2 | 40 | RoW | Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib | Shanghai Junshi Bioscience Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
NCT04061928: Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ |
|
|
| Not yet recruiting | 1/2 | 45 | NA | PD-1, Toripalimab | Peking University | PD-1, Chemoradiotherapy, Gastroesophageal Junction Cancer | 08/22 | 08/23 | | |
NCT04651127: Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer |
|
|
| Recruiting | 1/2 | 40 | RoW | Toripalimab + Chidamide | Sun Yat-sen University | Cervical Cancer, Cervix Cancer, Cervix Neoplasm | 09/22 | 09/23 | | |
NCT05103917: A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC |
|
|
| Enrolling by invitation | 1/2 | 24 | RoW | X4P-001, Toripalimab Injection | Abbisko Therapeutics Co, Ltd | Triple Negative Breast Cancer | 11/22 | 05/23 | | |
NCT04856631: A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer |
|
|
| Recruiting | 1/2 | 88 | RoW | Toripalimab Injection, Cetuximab Solution for infusion | Shanghai Junshi Bioscience Co., Ltd. | Head and Neck Squamous Cell Cancer | 11/22 | 11/23 | | |
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor |
|
|
| Terminated | 1/2 | 7 | RoW | TJ1133 Injection | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 02/23 | 02/23 | | |
NCT04929080: The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC |
|
|
| Completed | 1/2 | 149 | RoW | JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion, JS001 and JS004 | Shanghai Junshi Bioscience Co., Ltd. | Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma | 03/23 | 03/23 | | |
ChiCTR2000032293: An open-label, single-arm, phase Ib/II study of combination of toripalimab(PD-1 antibody), nab-paclitaxel, and gemcitabine as the first-line treatment for patients with advanced pancreatic ductal adenocarcinoma |
|
|
| Not yet recruiting | 1/2 | 54 | China | toripalimab plus nab-paclitaxel, and gemcitabine | West China Hospital of Sichuan University ; West China Hospital, Sichuan University, None known | advanced pancreatic cancer | | | | |
NCT05341193: PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 1/2 | 32 | RoW | Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab | Sun Yat-sen University, The First Hospital of Nanchang | Nasopharyngeal Carcinoma | 04/23 | 12/25 | | |
NCT03864211: Thermal Ablation Followed by Immunotherapy for HCC |
|
|
| Active, not recruiting | 1/2 | 145 | RoW | Thermal ablation, Toripalimab, Immunotherapy | Xiangya Hospital of Central South University | Hepatocellular Carcinoma Non-resectable | 05/23 | 05/23 | | |
NCT04988191: Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer |
|
|
| Recruiting | 1/2 | 44 | RoW | Toripalimab, Bevacizumab, Irinotecan | Peking University | Colorectal Carcinoma | 06/23 | 12/23 | | |
CT32, NCT04797702: Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. |
|
|
| Recruiting | 1/2 | 67 | RoW | Glumetinib combined with Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Relapsed or Metastatic Non-small Cell Lung Cancer | 07/23 | 02/24 | | |
ChiCTR2100048891: Study of the safety and efficacy of donafenib combined with toripalimab in patients with non-MSI-H metastatic colorectal cancer |
|
|
| Not yet recruiting | 1/2 | 35 | China | Donafenib + Toripalimab | Sichuan Cancer Hospital ; Sichuan Cancer Hospital, Suzhou Zelgen Biopharmaceuticals Co., Ltd. | colorectal cancer | | | | |
NCT05024812: Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1/2 | 64 | RoW | fruquintinib＋toripalimab + SOX | The First Affiliated Hospital of Zhengzhou University | Metastatic Gastric Cancer | 08/23 | 02/25 | | |
NCT05000684: Study of JS004 Combined With Toripalimab for Advanced Lung Cancer |
|
|
| Recruiting | 1/2 | 66 | RoW | JS004 in combination with toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Lung Cancer | 08/23 | 08/24 | | |
NCT05576961: Safety and Efficacy of RX-af01 Combined With PD-1 Antibody |
|
|
| Recruiting | 1/2 | 60 | RoW | RX-af01, Toripalimab, Mixed bacteria, High dose RX-af01 | Sun Yat-sen University | Solid Tumor, Immune Checkpoint Inhibitor, Intestinal Flora | 12/24 | 12/24 | | |
NCT06139211: A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 186 | RoW | JS015, Toripalimab, Paclitaxel, Irinotecan, Capecitabine, Oxaliplatin, Bevacizumab, Fluorouracil, Leucovorin, Gemcitabine, Albumin-Bound Paclitaxel | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Advanced Solid Tumor | 11/25 | 04/26 | | |
NCT04503902: Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1/2 | 46 | RoW | Donafenib Tosilate Tablets, Donafenib, Toripalimab Injection, JS001 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Advanced Hepatocellular Carcinoma | 12/23 | 12/23 | | |
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | LBL-007 Injection, LBL-007, Toripalimab Injection | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 07/24 | 12/24 | | |
NCT04914286: A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Completed | 1/2 | 148 | RoW | GFH018, Toripalimab | Zhejiang Genfleet Therapeutics Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/23 | | |
TREND, NCT04058470: Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma |
|
|
| Recruiting | 1/2 | 140 | RoW | Toripalimab, Rituximab, JS001, Rituximab, R-CHOP Protocol, Rituximab,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone | Huiqiang Huang | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma | 12/23 | 12/25 | | |
NCT04996771: Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 88 | RoW | Surufatinib,Etoposide,Cisplatin,Toripalimab, Surufatinib,Etoposide,Cisplatin | Sun Yat-sen University | Small Cell Lung Carcinoma | 12/23 | 12/24 | | |
NCT06208410: A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors |
|
|
| Recruiting | 1/2 | 306 | RoW | JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets, Toripalimab Injection, Paclitaxel for Injection (Albumin Bound), Fluzoparib Capsules, Pyrotinib Maleate Tablets, Capecitabine Tablets | Risen (Suzhou) Pharma Tech Co., Ltd. | Advanced Solid Tumors | 02/26 | 02/26 | | |
NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 20 | RoW | LM-302, Toripalimab, Tuoyi | LaNova Australia Pty Limited | Advanced Solid Tumor | 11/23 | 11/23 | | |
IUNU-PC-121, NCT06221774: Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors |
|
|
| Not yet recruiting | 1/2 | 42 | RoW | TT-00420 + Toripalimab | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Clear Cell Renal Carcinoma, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Cancer | 08/25 | 11/25 | | |
IN10018-010, NCT05830539: IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients |
|
|
| Active, not recruiting | 1/2 | 240 | RoW | IN10018+PLD, IN10018 and Doxorubicin Hydrochloride Liposome Injection, IN10018+PLD+Toripalimab, IN10018 and Doxorubicin Hydrochloride Liposome Injection and Toripalimab | InxMed (Shanghai) Co., Ltd. | Locally Advanced or Metastatic Solid Tumors | 03/24 | 12/24 | | |
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 95 | RoW | APG-115, Toripalimab | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Liposarcoma, Advanced Solid Tumor | 04/26 | 01/27 | | |
NCT04284488: Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors |
|
|
| Recruiting | 1/2 | 104 | RoW | APG-1387 for Injection, Toripalimab, JS001 | Ascentage Pharma Group Inc. | Advanced Solid Tumor | 04/24 | 04/24 | | |
| Not yet recruiting | 1/2 | 117 | RoW | JS001, Toripalimab, JS004, JS007, JS015, Irinotecan Liposome Injection, 5-Fluorouracil (5-FU), Leucovorin (LV), Nab paclitaxel, Gemcitabine | Fudan University | Pancreatic Cancer | 04/26 | 04/27 | | |
NCT06341400: RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients |
|
|
| Recruiting | 1/2 | 55 | RoW | DisitamabVedotinForIicction Toripalimab, radical cystectomy | Zhujiang Hospital | Bladder Cancer, Muscle-Invasive Bladder Carcinoma | 05/26 | 05/27 | | |
NCT06410703: CAN1012 Combined With PD-1 in Patients With Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 71 | RoW | CAN1012, Toripalimab | Canwell Biotech Limited | Advanced Solid Tumor | 05/25 | 05/26 | | |
NCT06462222: Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 34 | RoW | Toripalimab, pemetrexed | Guangzhou Medical University | Leptomeningeal Metastasis | 04/26 | 06/26 | | |
NCT05580445: Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 114 | RoW | CT-707, CT-707 granules, Toripalimab, Toripalimab injection, Gemcitabine, GEMZAR | Shouyao Holdings (Beijing) Co. LTD | Advanced Pancreatic Cancer | 08/24 | 08/24 | | |
NCT05173142: HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 141 | RoW | HMPL-453, gemcitabine and cisplatin, toripalimab, Docetaxel | Hutchison Medipharma Limited | Solid Tumor | 09/24 | 08/25 | | |
NCT05664971: JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer |
|
|
| Recruiting | 1/2 | 240 | RoW | Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection, Toripalimab, Docetaxel, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Etoposide | Shanghai Junshi Bioscience Co., Ltd. | Advanced Lung Cancer | 09/24 | 11/24 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05615974: A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors |
|
|
| Suspended | 1/2 | 145 | RoW | LM101, Toripalimab, Rituximab, Envafolimab | LaNova Medicines Limited | Malignant Tumors | 12/24 | 08/25 | | |
NCT05539118: Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma |
|
|
| Not yet recruiting | 1/2 | 48 | RoW | Recombinant human interferon α1b, Toripalimab, Anlotinib hydrochloride | Xijing Hospital | Melanoma | 12/24 | 12/26 | | |
| Recruiting | 1/2 | 84 | RoW | KD6001, Toripalimab, JS001 | Shanghai Kanda Biotechnology Co., Ltd. | Melanoma | 12/24 | 12/25 | | |
ChiCTR2200064196: A phase Ib/II, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of subcutaneous administration of DN1508052-01 combined with Toripalimab to adult patients with advanced solid tumors that progressed, intolerant to standard therapy or for which no standard therapy |
|
|
| Not yet recruiting | 1/2 | 254 | | SC/ivgtt | Beijing Cancer Hospital; Beijing Cancer Hospital, Shanghai De Novo Pharmatech Co., Ltd. | solid tumor | | | | |
NCT06117566: A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 100 | RoW | WX390, WXFL10030390, Toripalimab | Shanghai Jiatan Pharmatech Co., Ltd | Solid Tumor | 03/25 | 03/25 | | |
NCT05804526: A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 82 | RoW | RC88, Sintilimab Injection, Sintilimab | RemeGen Co., Ltd. | Advanced Solid Tumours | 05/25 | 12/25 | | |
JSFOL, NCT03985891: The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer |
|
|
| Recruiting | 1/2 | 40 | RoW | Anti-PD-1 Monoclonal Antibody JS001, Toripalimab, Chemotherapy, Folfox | Xiangya Hospital of Central South University | Colonic Neoplasms, Chemotherapy Effect | 06/25 | 06/26 | | |
NCT05518045: Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 392 | RoW | LM-108, Toripalimab | LaNova Medicines Limited | Advanced Solid Tumor | 07/25 | 10/25 | | |
NCT05821933: RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC |
|
|
| Recruiting | 1/2 | 106 | RoW | RC108, Furmonertinib, Toripalimab | RemeGen Co., Ltd. | NSCLC | 09/25 | 09/26 | | |
NCT05699811: IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 40 | RoW | MSC-IFNα, Nab paclitaxel, Abraxane, Cyclophosphamide, Anti-PD-1 monoclonal antibody, Toripalimab Injection, Sintilimab Injection, Camrelizumab Injection, Tislelizumab Injection | Chinese PLA General Hospital, Wuxi Sinotide New Drug Discovery Institutes | Locally Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1/2 | 22 | US | CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001 | Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd. | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma | 01/26 | 01/26 | | |
NCT05955105: A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies |
|
|
| Recruiting | 1/2 | 200 | RoW | ILB-2109, Toripalimab | Innolake Biopharm | Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Melanoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Classic Hodgkin Lymphoma | 01/26 | 07/26 | | |
HOPE-04, ChiCTR2200059970: Efficacy and safety of fractionation radiotherapy combined withToripalimab in high-risk / extremely high risk non muscle invasive bladder cancer |
|
|
| Recruiting | 1/2 | 55 | | 5x5Gy combined with immunotherapy | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Junshi company | Bladder cancer | | | | |
NCT06038396: A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 64 | RoW | RC118, RC118 for injection, Toripalimab, Toripalimab for injection, JS001 | RemeGen Co., Ltd. | Advanced Solid Tumor | 02/26 | 08/26 | | |
NCT06078670: PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 96 | NA | CVL218, Toripalimab、Paclitaxel For Injection (Albumin Bound)、Sintilimab、Paclitaxel Injection、Fruquintinib | Fujian Cancer Hospital | Advanced Solid Tumor | 06/26 | 06/26 | | |
NCT06079112: 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer |
|
|
| Not yet recruiting | 1/2 | 100 | RoW | 9MW2821, 9MW2821 injection, Toripalimab, Toripalimab injection | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Urothelial Carcinoma | 12/26 | 12/27 | | |
ACE-COMBO-02, CTR20222247: A Phase I clinical study to evaluate the efficacy and safety of recombinant humanized anti-HER2 monoclonal anti-AS269 conjugate (ARX788) in combination with toripalimab in patients with HER2-expressing or mutated advanced solid tumors |
|
|
| Recruiting | 1 | 85 | China | anvatabart opadotin (ARX788) - Ambrx, Loqtorzi (toripalimab) - Shanghai Junshi Biosci, Coherus Biosci | Zhejiang Xinma Biopharmaceutical Co., Ltd | HER2-expressing or mutated advanced solid tumors | | | | |
OrienX010-II-11, NCT04206358: Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma |
|
|
| Recruiting | 1 | 30 | RoW | OrienX010 combination with JS001, Recombinant Human GM-CSF Herpes Simplex Virus Injection combination with Recombinant Human Anti-PD-1 Monoclonal Antibody Injection | Peking University Cancer Hospital & Institute | Melanoma | 02/21 | 12/23 | | |
| Completed | 1 | 134 | RoW | CAR-CLDN18.2 T-Cells, Chimeric Antigen Receptor T Cells Targeting Claudin18.2, PD-1 Monoclonal Antibody, Toripalimab, Chemotherapy | Peking University, CARsgen Therapeutics Co., Ltd. | Advanced Solid Tumor | 03/21 | 01/24 | | |
ChiCTR1900022282: Radiotherapy and Toripalimab for Neoadjuvant Treatment of Resectable Esophageal Cancer |
|
|
| Not yet recruiting | 1 | 22 | China | toripalimab 240mg iv, Q3W, 4cycles; radiotherapy 41.4Gy/23fraction | Shandong Cancer Hospital ; Shandong Cancer Hospital, self-funding and company support | esophageal cancer | | | | |
Illuminate, NCT04473716: Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients |
|
|
| Completed | 1 | 20 | RoW | Toripalimab, Toripalimab for Injection, Paclitaxcel, Paclitaxel for Injection (Albumin Bound), Cisplatin, Cisplatin for Injection, Radical surgery, Post-operative radiotherapy/chemoradiotherapy | Shanghai Jiao Tong University School of Medicine | Oral Cancer, Induction Chemotherapy, Programmed Cell Death 1 Inhibitor, Inductive Therapy | 04/21 | 09/23 | | |
NCT03966209: Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant |
|
|
| Recruiting | 1 | 20 | RoW | JS001(PD-1 inhibitor) | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Liver Transplantation | 04/21 | 10/22 | | |
| Active, not recruiting | 1 | 33 | RoW | OrienX010 Combination with Toripalimab injection, Recombinant Human GM-CSF Herpes Simplex Virus intratumoral Injection combination with Recombinant Human Anti-PD-1 Monoclonal Antibody infusion | Peking University Cancer Hospital & Institute | Melanoma | 05/21 | 05/25 | | |
ECCT, NCT04046185: Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer |
|
|
| Not yet recruiting | 1 | 60 | NA | PD-1 inhibitor combined progesterone, Toripalimab combine with progesterone, progesterone | Shanghai First Maternity and Infant Hospital | Endometrial Cancer Stage I | 10/21 | 10/22 | | |
NCT04073784: Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. |
|
|
| Active, not recruiting | 1 | 41 | RoW | Gemcitabine combined with Aptinib and Toripalimab | Sun Yat-sen University | Nasopharyngeal Carcinoma | 04/22 | 04/24 | | |
NCT04731038: Combination Therapy for First Line Treatment of Advanced Cervical Cancer |
|
|
| Recruiting | 1 | 20 | RoW | Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin | Ruijin Hospital | Advanced Cervical Cancer | 07/22 | 07/24 | | |
| Terminated | 1 | 18 | RoW | LM-061, Kinase inhibitor, Toripalimab | LaNova Medicines Limited | Advanced Tumours | 07/22 | 12/22 | | |
NCT03474640: Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies |
|
|
| Active, not recruiting | 1 | 198 | US | Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody, TAB001, JS001 | Shanghai Junshi Bioscience Co., Ltd., TopAlliance Biosciences, Inc., Iqvia Pty Ltd | Advanced Malignancies | 08/22 | 08/23 | | |
ChiCTR2000035782: A prospective, one-arm, phase I study of high-memory phenotypic tumor-infiltrating T lymphocytes (TILs) combined with teriprizumab in the treatment of advanced melanoma |
|
|
| Recruiting | 1 | 9 | China | TIL and Treprizumab | Zhongshan Hospital, Fudan University ; Zhongshan Hospital, Fudan University, Shanghai shenkang hospital development center | Melanoma | | | | |
ChiCTR1900026158: Safety and efficacy of lenvaltinib combined with terepril monoclonal antibody, a PD1 inhibitor, in the treatment of unresectable intrahepatic cholangiocarcinoma |
|
|
| Not yet recruiting | 1 | 50 | China | Lenvatinib plus treprizumab, an inhibitor of PD1 | The Second Affiliated hospital of Zhejiang University School of Medicine ; The Second Affiliated hospital of Zhejiang University School of Medicine, Hubei Chen Xiaoping Science and Technology Development Foundation | unresectable intrahepatic cholangiocarcinom | | | | |
DETECTOR-1, NCT04926753: Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer |
|
|
| Recruiting | 1 | 20 | RoW | 5-Fluorouracil, Cisplatin, Toripalimab | Ruijin Hospital | Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer | 12/22 | 06/24 | | |